Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Kuros Biosciences (0RHR) Share Price & Analysis

0RHR Stock Chart & Stats

CHF 20.98-CHF 0.02(-0.10%)
At close: 4:30 PM GMT
CHF 17.5CHF 20CHF 22.53 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
CHF 20.84 - CHF 21.00
52-Week Range
CHF 16.46 - CHF 32.48
Previous Close
CHF 21.00
Volume
9,171
Average Volume (3M)
17.83K
Market Cap
CHF 820.58M
Enterprise Value
CHF 776.03M
Total Cash (Recent Filing)
CHF 7.85M
Total Debt (Recent Filing)
CHF 11.01M
Price to Earnings (P/E)
114.0
Beta
0.93
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
0.08
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Growth And Profitability Inflection

Strong sales growth combined with a first half-year profit demonstrates meaningful commercial scaling and improving operating leverage. If execution continues, the expanding revenue base can support reinvestment, strengthen market position, and improve earnings durability over the next several quarters.

High Gross Margins And Conservative Leverage

Very high gross margins provide substantial economic value per product sold, while minimal leverage limits interest burden and financial stress. This combination gives Kuros greater flexibility to fund commercialization and manufacturing investments without relying heavily on additional debt.

Commercial Reach And Market-share Expansion

Broader distribution, increasing surgeon utilization, and a rapidly expanding treated-patient base indicate improving adoption of MagnetOs. These gains can create a durable commercial platform, support repeat demand, and increase the effectiveness of future sales investments.

Bears Say

Weak Cash Conversion And Working-capital Pressure

Cash generation has lagged accounting earnings, with operating and free cash flow turning negative after positive prior-year figures. Elevated receivables and continued investment can increase funding sensitivity, limiting flexibility if conversion does not improve as the business scales.

Manufacturing Ramp And Transformation Costs May Dilute Margins

Building U.S. production and expanding operational infrastructure should support localization over time, but the transition creates near-term cost pressure before benefits are realized. Lower margins during the ramp could delay operating leverage and make earnings more sensitive to execution.

Profitability Remains Thin Despite Recent Improvement

The move into profitability is encouraging, but a 1.7% net margin leaves limited protection against slower growth, cost increases, or temporary commercialization expenses. Kuros therefore remains dependent on sustained expansion and further margin improvement to establish durable earnings resilience.

Kuros Biosciences News

0RHR FAQ

What was Kuros Biosciences’s price range in the past 12 months?
Kuros Biosciences lowest share price was CHF16.46 and its highest was CHF32.48 in the past 12 months.
What is Kuros Biosciences’s market cap?
Kuros Biosciences’s market cap is CHF820.58M.
When is Kuros Biosciences’s upcoming earnings report date?
Kuros Biosciences’s next earnings report is estimated for Mar 03, 2027 (not yet confirmed), which is in 122 days.
How were Kuros Biosciences’s earnings last quarter?
Kuros Biosciences released its earnings results on Aug 13, 2026. The company reported CHF0.06 earnings per share for the quarter, beating the consensus estimate of CHF0.06 by CHF0.001.
Is Kuros Biosciences overvalued?
According to Wall Street analysts Kuros Biosciences’s price is currently Undervalued.
Does Kuros Biosciences pay dividends?
Kuros Biosciences does not currently pay dividends.
What is Kuros Biosciences’s EPS estimate?
Kuros Biosciences’s EPS estimate is 0.08.
How many shares outstanding does Kuros Biosciences have?
Kuros Biosciences has 39,756,700 shares outstanding.
What happened to Kuros Biosciences’s price movement after its last earnings report?
Kuros Biosciences reported an EPS of CHF0.06 in its last earnings report, beating expectations of CHF0.06. Following the earnings report the stock price went up 3.304%.
Which hedge fund is a major shareholder of Kuros Biosciences?
Currently, no hedge funds are holding shares in GB:0RHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology